View Financial HealthBioNexus Gene Lab 배당 및 자사주 매입배당 기준 점검 0/6BioNexus Gene Lab 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-5.3%자사주 매입 수익률총 주주 수익률-5.3%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 01BioNexus Gene Lab Corp. announced delayed annual 10-K filingOn 03/31/2026, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.New Risk • Mar 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (US$5.32m market cap). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).New Risk • Dec 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (US$9.81m market cap).Reported Earnings • Nov 17Third quarter 2025 earnings released: US$0.40 loss per share (vs US$0.75 loss in 3Q 2024)Third quarter 2025 results: US$0.40 loss per share (improved from US$0.75 loss in 3Q 2024). Revenue: US$2.54m (down 3.3% from 3Q 2024). Net loss: US$709.0k (loss narrowed 47% from 3Q 2024).공시 • Nov 17BioNexus Gene Lab Corp., Annual General Meeting, Dec 24, 2025BioNexus Gene Lab Corp., Annual General Meeting, Dec 24, 2025.공시 • Nov 08BioNexus Gene Lab Corp. has filed a Follow-on Equity Offering in the amount of $3.557 million.BioNexus Gene Lab Corp. has filed a Follow-on Equity Offering in the amount of $3.557 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering공시 • Aug 15BioNexus Gene Lab Corp. announced delayed 10-Q filingOn 08/14/2025, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jun 26Bionexus Gene Lab Corp. Announces CFO Changes, Effective June 17, 2025On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately. Ms. Chong, age 62, has over 25 years of senior financial leadership experience, including serving as the Chief Financial Officer of Avillion Berhad from 2013 until November 2024. She is a member of the Association of Chartered Certified Accountants (ACCA) and the Malaysian Institute of Accountants (MIA), and brings deep expertise in corporate financial reporting, internal controls, and regional operations oversight. Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.공시 • Apr 01BioNexus Gene Lab Corp. announced delayed annual 10-K filingOn 03/31/2025, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.Board Change • Feb 14High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Chee Yap is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공시 • Jan 03Hearing Panel of Nasdaq Grants Temporary Exception to BioNexus Gene Lab to Regain Compliance with Bid Price RuleOn December 27, 2024, BioNexus Gene Lab Corp. received a written notice from the Nasdaq Hearings Panel indicating that the Company has been granted a temporary exception to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Company has until May 1, 2025, to regain compliance. As part of this compliance plan, the Company intends to effect a reverse stock split, if necessary, no later than April 7, 2025, and has outlined steps to meet this timeline. Failure to regain compliance by May 1, 2025, will result in the delisting of the Company’s common stock from The Nasdaq Capital Market. Additionally, Nasdaq has updated its rules regarding reverse stock splits. Effective January 30, 2025, the Company must notify Nasdaq of specific details, including the date of shareholder approval, at least ten (10) calendar days prior to the anticipated market effective date of the reverse stock split. The Company is taking the necessary steps to ensure compliance with the Bid Price Rule within the granted timeframe and will provide updates as appropriate.공시 • Nov 15BioNexus Gene Lab Corp. announced delayed 10-Q filingOn 11/14/2024, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Nov 09BioNexus Gene Lab Submits Formal Request for Hearing Before Nasdaq Hearings Panel to Appeal the Delisting DeterminationOn November 5, 2024, BioNexus Gene Lab Corp. (the "Company") received a notification from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company's common stock will be delisted from the Nasdaq Capital Market due to its failure to comply with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1 per share. The Company had been provided two consecutive 180-day grace periods, ending on November 4, 2024, to regain compliance but was unable to meet the requirement within the designated period. In response, on November 8, 2024, the Company submitted a formal request for a hearing before a Nasdaq Hearings Panel to appeal the delisting determination. The Nasdaq Hearings Department has acknowledged receipt of the Company's hearing request, which stays the suspension of trading of the Company's common stock pending a decision by the Panel. The Company intends to present a compliance plan at the hearing, including potential corrective actions such as a reverse stock split, among other strategic initiatives, to regain compliance with Nasdaq's listing standards.공시 • Oct 18Bionexus Gene Lab Corp. Announces Resignation of Wei Foong Lim and Koon Wai Wong as Members of the Board of Directors and Member of the Audit Committee, and A Member of the Corporate Governance and Nominating CommitteeOn October 9, 2024, Mr. Wei Foong Lim and Mr. Koon Wai Wong resigned in their capacities as members of the Board of Directors of BioNexus Gene Lab Corp., effective immediately. Mr. Wong was also a Member of the Audit Committee, and a Member of the Corporate Governance and Nominating Committee.공시 • Sep 10BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024.Reported Earnings • Aug 16Second quarter 2024 earnings released: US$0.005 loss per share (vs US$0.018 loss in 2Q 2023)Second quarter 2024 results: US$0.005 loss per share (improved from US$0.018 loss in 2Q 2023). Revenue: US$11.9k (down 100% from 2Q 2023). Net loss: US$93.4k (loss narrowed 64% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.Board Change • Jun 28High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Chee Yap is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • May 10The Nasdaq Stock Market Determines BioNexus Gene Lab Eligible for an Additional 180 Calendar Day Extension Period or Until November 4, 2024 to Regain Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2)On November 6, 2023, BioNexus Gene Lab Corp. (the ‘Company’) reported that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (‘Nasdaq’) regarding the Company’s failure to comply with Nasdaq Continued Listing Rule (‘Rule’) 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. A failure to comply with Rule 5550(a)(2) exists when listed securities fail to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days. Under Rule 5810(c)(3)(A), the Company automatically was provided a period of 180 calendar days, until May 6, 2024, to regain compliance. The Company requested in writing an additional 180-calendar day compliance period after the expiration of the Initial Period to regain compliance with the Nasdaq requirements and informed Nasdaq of its intention to cure the deficiency during any second compliance period extension by effecting a reverse stock split, if necessary. On May 8, 2024, the Company received notification from NASDAQ that, after an analysis of the requirements under Nasdaq Listing Rule 5810 (c)(3)(A), the Staff determined that the Company is eligible for an additional 180 calendar day extension period (the ‘Additional Period’), or until November 4, 2024. If at any time during this 180-day period the closing bid price of the Company’s securities is at least $1.00 for a minimum of ten consecutive business days, the Company’s compliance will be regained. In the event that the Company is not able to cure the bid price deficiency during the Additional Period, the Staff will provide written notice that the Common Stock will be delisted; however, the Company may request a hearing before the Nasdaq Hearings Panel (the ‘Panel’), which request, if timely made, would stay any further suspension or delisting action by the Staff pending the conclusion of the hearing process and expiration of any extension that may be granted by the Panel. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq listing criteria.공시 • Mar 29BioNexus Gene Lab Corp. announced delayed annual 10-K filingOn 03/28/2024, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.분석 기사 • Feb 14BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stocks Shoot Up 234% But Its P/S Still Looks ReasonableDespite an already strong run, BioNexus Gene Lab Corp. ( NASDAQ:BGLC ) shares have been powering on, with a gain of...Board Change • Feb 14High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. President & Director Yee Wong is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Jan 17Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab CorpOn January 17, 2024, Soo Kow Lai, Chan Chong Wong, Liong Tai Tan, Too Kam Tham, Kim Hai Wong announced that on December 11, 2023, Soo Kow Lai, Chan Chong Wong, Liong Tai Tan, Too Kam Tham, Kim Hai Wong executed a Written Consent to Action Without Meeting of the Shareholders (the Written Consent) removing the certain Board members and appointing three new board members of the shareholders’ choosing.공시 • Nov 15BioNexus Gene Lab Corp. announced delayed 10-Q filingOn 11/14/2023, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Nov 14BioNexus Gene Lab Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2)On November 6, 2023, BioNexus Gene Lab Corp. (the ‘Company’) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (‘Nasdaq’) regarding the Company’s failure to comply with Nasdaq Continued Listing Rule (‘Rule’) 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. A failure to comply with Rule 5550(a)(2) exists when listed securities fail to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days. Based on the closing bid price for the last 33 consecutive business days (including, in particular, the period September 20, 2023 through November 3, 2023), the Company failed to meet the aforesaid requirement. Under Rule 5810(c)(3)(A), the Company will be provided a compliance period of 180 calendar days, until May 6, 2024, to regain compliance. If at any time during this 180-day period the closing bid price of the Company’s securities is at least $1.00 for a minimum of ten consecutive business days, the Company’s compliance will be regained. In the event the Company does not regain compliance in the first compliance period, it may be eligible to apply for an additional 180 calendar days to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement. The Company will also need to provide written notice of its intention to cure the deficiency during the second compliance period. However, if it appears to the Nasdaq staff that the Company will neither be able nor otherwise eligible to cure the deficiency, it may be subject to delisting by Nasdaq. The letter has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on The Nasdaq Capital Market, subject to the Company’s compliance with the other listing requirements of The Nasdaq Capital Market. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq listing criteria.Board Change • Nov 14High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. President & Director Yee Wong is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Oct 17+ 1 more updateBioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive OfficerOn October 12, 2023, the board of directors of the BioNexus Gene Lab Corp. approved the appointment of Mr. Chi Yuen Leong as the Chief Executive Officer, effective October 12, 2023. Mr. Leong, aged 72, has extensive experience in management, commercialization, finance, and the biotechnology industry. He served as the President and director from the Company's inception to August 2022 and has been working with and guiding the Company's successful listing on OTC and Nasdaq. He joined the US Arem Pacific Corporation as the Chief Executive Officer from March 1, 2009, until September 30, 2015. Mr. Leong received a Bachelor of Behavioral Sciences from the University of East Asia, Malaysia. Mr. Leong brings a wide range of business experience, including experience with public companies, to their board of directors.공시 • Oct 12+ 1 more updateBioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Chief Executive OfficerBioNexus Gene Lab Corp. On October 4, 2023, Mr. Sook Keng Yeoh, the Chief Executive Officer tendered his resignation letter to Bionexus Gene Lab Corp. from his positions at the Company. The Company and Mr. Sook Keng Yeoh agreed that the resignations would be effective October 4, 2023. Mr. Sook Keng Yeoh’s resignation is not due to any disagreement with the Company, the Company’s management, or the Board on any matter relating to the Company’s operations, policies, or practices (financial or otherwise).공시 • Sep 09BioNexus Gene Lab Corp. Announces Executive ChangesBioNexus Gene Lab Corp. announced on August 1, 2023, Mr. Liong Tai Tan, the Chief Operating Officer and a member of the Board of Directors, notified Bionexus Gene Lab Corp. (the Company) of his desire to resign from his position at the Company. The Company and Mr. Liong Tai Tan agreed that the resignations would be effective August 31, 2023. Mr. Liong Tai Tan’s resignation is not due to any disagreement with the Company, the Company's management or the Board on any matter relating to the Company’s operations, policies, or practices (financial or otherwise), Mr. Liong Tai Tan informed the Company that he is leaving the Company and the Board of Directors to pursue other commitments. On August 2, 2023, the Board of Directors of the Company approved the appointment of Mr. Lee Su-Leng Tan as the Chief Operating Officer and not a director, effective September 1, 2023. Mr. Tan, aged 40, has over 20 years of extensive experience in industries including Information Systems, Hospitality, Investment Management, Construction, Property Development, Travel, Government Liaison, and Life Sciences, primarily focused on commercialization, finance, and general management. From 2022 to August 2023, Mr. Tan worked as the Chief Commercial Officer for Dryox Health Limited, a startup focused on repurposing drugs for unmet needs in the dermatological space, specifically anticholinergic drugs. From 2017 to August 2023, Mr. Tan worked as the FLO Life Sciences Group’s owner and the Managing Director at Biotechnology Group, focusing on infectious diseases and oncology pre-clinical drug candidates and clinical research. From 2018 to 2019, Mr. Tan was the President of Avillion Berhad, a publicly listed travel and hospitality group with hotels, commercial property, and inbound/outbound travel services.New Risk • Aug 17New major risk - Revenue and earnings growthEarnings have declined by 7.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (67% average weekly change). Earnings have declined by 7.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (US$11.5m market cap).Reported Earnings • Aug 17Second quarter 2023 earnings released: US$0.001 loss per share (vs US$0.01 loss in 2Q 2022)Second quarter 2023 results: US$0.001 loss per share. Revenue: US$2.57m (up 3.3% from 2Q 2022). Net loss: US$259.3k (loss widened 87% from 2Q 2022).New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (70% average weekly change). Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (US$55.7m market cap).Board Change • Jul 21High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. COO & Executive Director Liong Tan is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공시 • Feb 16BioNexus Gene Lab Corporation has filed an IPO in the amount of $17.25 million.BioNexus Gene Lab Corporation has filed an IPO in the amount of $17.25 million. Security Name: Common Stock Security Type: Common Stock공시 • Aug 18+ 1 more updateBionexus Gene Lab Corporation Announces Management ChangesBioNexus Gene Lab Corporation announced that on August 9, 2022, Mr. Soo Kow Lai, the Chairman and director, Mr. Chan Chong Wong, the Chief Executive Officer and director, and Mr. Chi Yuen Leong, the President and director, notified that their desire to resign from their positions at the Company. The Company and Mr. Soo Kow Lai, Mr. Chan Chong Wong, and Mr. Chi Yuen Leong agreed that the resignations would be effective August 12, 2022. Mr. Soo Kow Lai, Mr. Chan Chong Wong, and Mr. Chi Yuen Leong’s resignations do not involve any disagreement on any matter relating to the Company’s operations, policies or practices (financial or otherwise), but were in order to pursue other commitments. On August 9, 2022, the Board of Directors of the Company approved the appointments of Mr. Yeat Min Fong as the Chairman and director, Mr. Sook Keng Yeoh as director, and Ms. Yee Meng Wong as the President and director, effective August 9, 2022. The biographical information of Mr. Yeat Min Fong, Mr. Sook Keng Yeoh, and Mr. Yee Meng Wong are set out below: Mr. Yeat Min Fong, age 43, has over 15 years of extensive experience in the medical industry. From 2020 to 2022, Mr. Fong was the Country General Manager of Malaysia of Doctor Anywhere, responsible for all business activities in the country. From 2014 to 2020, Mr. Fong acted as the General Manager/Medical Director of iHeal Medical Centre, where he performed numerous heart surgeries. Before entering the private medical industry, Mr. Fong engaged in various public hospitals in Malaysia for seven years. Mr. Fong holds a Bachelor of Medicine and Bachelor of Surgery from Manipal Acade MY of Higher Education in Manipal, India and a Master of Business Administration from the University of Cardiff Metropolitan in the UK. Mr. Sook Keng Yeoh, age 63, has over 41 years of extensive experience in management. From 2019 to 2022, Mr. Yeoh served as a director at ADS Sentral Sdn Bhd. From 1999 to 2019, Mr. Yeoh was the Chief Financial Officer and Finance Director of TRC Synergy Bhd., the Chief Executive Officer of TRC Energy Sdn Bhd. and the Executive Director of PetroBru (B) Sdn Bhd., a TRC Group. Mr. Yeoh holds a Bachelor of Commerce in Accounting, Finance, and Systems from the University of New South Wales (Australia) and a Chartered Accountant with the Malaysian Institute of Accountants. Ms. Yee Meng Wong, age 37, has many experiences in the biochemical industry and more than ten years of research experience. From 2016 to 2022, Ms. Wong served as a tutor and a lecturer at Monash University and as a consultant with Biomass Power Plant, Soybean Waste Aerobic Composting Plant, Deep Tech Startup Ultra Battery, and Food Safety & Handling, where she solved a series of biotech issues.공시 • Apr 03BioNexus Gene Lab Corporation announced delayed annual 10-K filingOn 04/01/2022, BioNexus Gene Lab Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.공시 • May 18BioNexus Gene Lab Corporation announced delayed 10-Q filingOn 05/17/2021, BioNexus Gene Lab Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공시 • Jan 01BioNexus Gene Lab Corporation (OTCPK:BGLC) agreed to acquire Chemrex Corporation Sdn. Bhd.BioNexus Gene Lab Corporation (OTCPK:BGLC) agreed to acquire Chemrex Corporation Sdn. Bhd. on December 24, 2020. Under terms, BioNexus Gene Lab Corporation will issue 68.48 million shares. As of December 31, 2019 Chemrex generated a revenue of $15.6 million and net income of $.30 million. Post acquisition Chemrex will become wholly-owned subsidiary of BioNexus. The transaction is subject to regulatory approvals. The transaction is expected to close on December 31, 2020.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 BGLC 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: BGLC 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장BioNexus Gene Lab 배당 수익률 vs 시장BGLC의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (BGLC)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.3%업계 평균 (Trade Distributors)1.4%분석가 예측 (BGLC) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 BGLC 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 BGLC 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 BGLC 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: BGLC 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 11:13종가2026/05/21 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스BioNexus Gene Lab Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 01BioNexus Gene Lab Corp. announced delayed annual 10-K filingOn 03/31/2026, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
New Risk • Mar 17New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (US$5.32m market cap). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
New Risk • Dec 14New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 63% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Market cap is less than US$10m (US$9.81m market cap).
Reported Earnings • Nov 17Third quarter 2025 earnings released: US$0.40 loss per share (vs US$0.75 loss in 3Q 2024)Third quarter 2025 results: US$0.40 loss per share (improved from US$0.75 loss in 3Q 2024). Revenue: US$2.54m (down 3.3% from 3Q 2024). Net loss: US$709.0k (loss narrowed 47% from 3Q 2024).
공시 • Nov 17BioNexus Gene Lab Corp., Annual General Meeting, Dec 24, 2025BioNexus Gene Lab Corp., Annual General Meeting, Dec 24, 2025.
공시 • Nov 08BioNexus Gene Lab Corp. has filed a Follow-on Equity Offering in the amount of $3.557 million.BioNexus Gene Lab Corp. has filed a Follow-on Equity Offering in the amount of $3.557 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
공시 • Aug 15BioNexus Gene Lab Corp. announced delayed 10-Q filingOn 08/14/2025, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jun 26Bionexus Gene Lab Corp. Announces CFO Changes, Effective June 17, 2025On June 17, 2025, the Board of Directors of BioNexus Gene Lab Corp. (the “Company”) appointed Ms. Chong Set Fui (Angeline) as the Company’s Chief Financial Officer and Principal Financial Officer, effective immediately. Ms. Chong, age 62, has over 25 years of senior financial leadership experience, including serving as the Chief Financial Officer of Avillion Berhad from 2013 until November 2024. She is a member of the Association of Chartered Certified Accountants (ACCA) and the Malaysian Institute of Accountants (MIA), and brings deep expertise in corporate financial reporting, internal controls, and regional operations oversight. Mr. Su-Leng Tan Lee ceased his role as acting Chief Financial Officer and Principal Financial Officer of the Company.
공시 • Apr 01BioNexus Gene Lab Corp. announced delayed annual 10-K filingOn 03/31/2025, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Board Change • Feb 14High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Chee Yap is the most experienced director on the board, commencing their role in 2022. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공시 • Jan 03Hearing Panel of Nasdaq Grants Temporary Exception to BioNexus Gene Lab to Regain Compliance with Bid Price RuleOn December 27, 2024, BioNexus Gene Lab Corp. received a written notice from the Nasdaq Hearings Panel indicating that the Company has been granted a temporary exception to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. The Company has until May 1, 2025, to regain compliance. As part of this compliance plan, the Company intends to effect a reverse stock split, if necessary, no later than April 7, 2025, and has outlined steps to meet this timeline. Failure to regain compliance by May 1, 2025, will result in the delisting of the Company’s common stock from The Nasdaq Capital Market. Additionally, Nasdaq has updated its rules regarding reverse stock splits. Effective January 30, 2025, the Company must notify Nasdaq of specific details, including the date of shareholder approval, at least ten (10) calendar days prior to the anticipated market effective date of the reverse stock split. The Company is taking the necessary steps to ensure compliance with the Bid Price Rule within the granted timeframe and will provide updates as appropriate.
공시 • Nov 15BioNexus Gene Lab Corp. announced delayed 10-Q filingOn 11/14/2024, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Nov 09BioNexus Gene Lab Submits Formal Request for Hearing Before Nasdaq Hearings Panel to Appeal the Delisting DeterminationOn November 5, 2024, BioNexus Gene Lab Corp. (the "Company") received a notification from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company's common stock will be delisted from the Nasdaq Capital Market due to its failure to comply with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1 per share. The Company had been provided two consecutive 180-day grace periods, ending on November 4, 2024, to regain compliance but was unable to meet the requirement within the designated period. In response, on November 8, 2024, the Company submitted a formal request for a hearing before a Nasdaq Hearings Panel to appeal the delisting determination. The Nasdaq Hearings Department has acknowledged receipt of the Company's hearing request, which stays the suspension of trading of the Company's common stock pending a decision by the Panel. The Company intends to present a compliance plan at the hearing, including potential corrective actions such as a reverse stock split, among other strategic initiatives, to regain compliance with Nasdaq's listing standards.
공시 • Oct 18Bionexus Gene Lab Corp. Announces Resignation of Wei Foong Lim and Koon Wai Wong as Members of the Board of Directors and Member of the Audit Committee, and A Member of the Corporate Governance and Nominating CommitteeOn October 9, 2024, Mr. Wei Foong Lim and Mr. Koon Wai Wong resigned in their capacities as members of the Board of Directors of BioNexus Gene Lab Corp., effective immediately. Mr. Wong was also a Member of the Audit Committee, and a Member of the Corporate Governance and Nominating Committee.
공시 • Sep 10BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024BioNexus Gene Lab Corp., Annual General Meeting, Oct 04, 2024.
Reported Earnings • Aug 16Second quarter 2024 earnings released: US$0.005 loss per share (vs US$0.018 loss in 2Q 2023)Second quarter 2024 results: US$0.005 loss per share (improved from US$0.018 loss in 2Q 2023). Revenue: US$11.9k (down 100% from 2Q 2023). Net loss: US$93.4k (loss narrowed 64% from 2Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.
Board Change • Jun 28High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Chee Yap is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • May 10The Nasdaq Stock Market Determines BioNexus Gene Lab Eligible for an Additional 180 Calendar Day Extension Period or Until November 4, 2024 to Regain Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2)On November 6, 2023, BioNexus Gene Lab Corp. (the ‘Company’) reported that it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (‘Nasdaq’) regarding the Company’s failure to comply with Nasdaq Continued Listing Rule (‘Rule’) 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. A failure to comply with Rule 5550(a)(2) exists when listed securities fail to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days. Under Rule 5810(c)(3)(A), the Company automatically was provided a period of 180 calendar days, until May 6, 2024, to regain compliance. The Company requested in writing an additional 180-calendar day compliance period after the expiration of the Initial Period to regain compliance with the Nasdaq requirements and informed Nasdaq of its intention to cure the deficiency during any second compliance period extension by effecting a reverse stock split, if necessary. On May 8, 2024, the Company received notification from NASDAQ that, after an analysis of the requirements under Nasdaq Listing Rule 5810 (c)(3)(A), the Staff determined that the Company is eligible for an additional 180 calendar day extension period (the ‘Additional Period’), or until November 4, 2024. If at any time during this 180-day period the closing bid price of the Company’s securities is at least $1.00 for a minimum of ten consecutive business days, the Company’s compliance will be regained. In the event that the Company is not able to cure the bid price deficiency during the Additional Period, the Staff will provide written notice that the Common Stock will be delisted; however, the Company may request a hearing before the Nasdaq Hearings Panel (the ‘Panel’), which request, if timely made, would stay any further suspension or delisting action by the Staff pending the conclusion of the hearing process and expiration of any extension that may be granted by the Panel. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq listing criteria.
공시 • Mar 29BioNexus Gene Lab Corp. announced delayed annual 10-K filingOn 03/28/2024, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
분석 기사 • Feb 14BioNexus Gene Lab Corp. (NASDAQ:BGLC) Stocks Shoot Up 234% But Its P/S Still Looks ReasonableDespite an already strong run, BioNexus Gene Lab Corp. ( NASDAQ:BGLC ) shares have been powering on, with a gain of...
Board Change • Feb 14High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. President & Director Yee Wong is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Jan 17Soo Kow Lai Provides Information to Shareholders of BioNexus Gene Lab CorpOn January 17, 2024, Soo Kow Lai, Chan Chong Wong, Liong Tai Tan, Too Kam Tham, Kim Hai Wong announced that on December 11, 2023, Soo Kow Lai, Chan Chong Wong, Liong Tai Tan, Too Kam Tham, Kim Hai Wong executed a Written Consent to Action Without Meeting of the Shareholders (the Written Consent) removing the certain Board members and appointing three new board members of the shareholders’ choosing.
공시 • Nov 15BioNexus Gene Lab Corp. announced delayed 10-Q filingOn 11/14/2023, BioNexus Gene Lab Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Nov 14BioNexus Gene Lab Receives Letter from Nasdaq Regarding Non-Compliance with Minimum Bid Price Per Share with Nasdaq Continued Listing Rule 5550(a)(2)On November 6, 2023, BioNexus Gene Lab Corp. (the ‘Company’) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (‘Nasdaq’) regarding the Company’s failure to comply with Nasdaq Continued Listing Rule (‘Rule’) 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. A failure to comply with Rule 5550(a)(2) exists when listed securities fail to maintain a closing bid price of at least $1.00 per share for 30 consecutive business days. Based on the closing bid price for the last 33 consecutive business days (including, in particular, the period September 20, 2023 through November 3, 2023), the Company failed to meet the aforesaid requirement. Under Rule 5810(c)(3)(A), the Company will be provided a compliance period of 180 calendar days, until May 6, 2024, to regain compliance. If at any time during this 180-day period the closing bid price of the Company’s securities is at least $1.00 for a minimum of ten consecutive business days, the Company’s compliance will be regained. In the event the Company does not regain compliance in the first compliance period, it may be eligible to apply for an additional 180 calendar days to regain compliance. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement. The Company will also need to provide written notice of its intention to cure the deficiency during the second compliance period. However, if it appears to the Nasdaq staff that the Company will neither be able nor otherwise eligible to cure the deficiency, it may be subject to delisting by Nasdaq. The letter has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on The Nasdaq Capital Market, subject to the Company’s compliance with the other listing requirements of The Nasdaq Capital Market. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other Nasdaq listing criteria.
Board Change • Nov 14High number of new and inexperienced directorsThere are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. President & Director Yee Wong is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Oct 17+ 1 more updateBioNexus Gene Lab Corp. Appoints Mr. Chi Yuen Leong as the Chief Executive OfficerOn October 12, 2023, the board of directors of the BioNexus Gene Lab Corp. approved the appointment of Mr. Chi Yuen Leong as the Chief Executive Officer, effective October 12, 2023. Mr. Leong, aged 72, has extensive experience in management, commercialization, finance, and the biotechnology industry. He served as the President and director from the Company's inception to August 2022 and has been working with and guiding the Company's successful listing on OTC and Nasdaq. He joined the US Arem Pacific Corporation as the Chief Executive Officer from March 1, 2009, until September 30, 2015. Mr. Leong received a Bachelor of Behavioral Sciences from the University of East Asia, Malaysia. Mr. Leong brings a wide range of business experience, including experience with public companies, to their board of directors.
공시 • Oct 12+ 1 more updateBioNexus Gene Lab Corp. Announces Resignation of Sook Keng Yeoh as Chief Executive OfficerBioNexus Gene Lab Corp. On October 4, 2023, Mr. Sook Keng Yeoh, the Chief Executive Officer tendered his resignation letter to Bionexus Gene Lab Corp. from his positions at the Company. The Company and Mr. Sook Keng Yeoh agreed that the resignations would be effective October 4, 2023. Mr. Sook Keng Yeoh’s resignation is not due to any disagreement with the Company, the Company’s management, or the Board on any matter relating to the Company’s operations, policies, or practices (financial or otherwise).
공시 • Sep 09BioNexus Gene Lab Corp. Announces Executive ChangesBioNexus Gene Lab Corp. announced on August 1, 2023, Mr. Liong Tai Tan, the Chief Operating Officer and a member of the Board of Directors, notified Bionexus Gene Lab Corp. (the Company) of his desire to resign from his position at the Company. The Company and Mr. Liong Tai Tan agreed that the resignations would be effective August 31, 2023. Mr. Liong Tai Tan’s resignation is not due to any disagreement with the Company, the Company's management or the Board on any matter relating to the Company’s operations, policies, or practices (financial or otherwise), Mr. Liong Tai Tan informed the Company that he is leaving the Company and the Board of Directors to pursue other commitments. On August 2, 2023, the Board of Directors of the Company approved the appointment of Mr. Lee Su-Leng Tan as the Chief Operating Officer and not a director, effective September 1, 2023. Mr. Tan, aged 40, has over 20 years of extensive experience in industries including Information Systems, Hospitality, Investment Management, Construction, Property Development, Travel, Government Liaison, and Life Sciences, primarily focused on commercialization, finance, and general management. From 2022 to August 2023, Mr. Tan worked as the Chief Commercial Officer for Dryox Health Limited, a startup focused on repurposing drugs for unmet needs in the dermatological space, specifically anticholinergic drugs. From 2017 to August 2023, Mr. Tan worked as the FLO Life Sciences Group’s owner and the Managing Director at Biotechnology Group, focusing on infectious diseases and oncology pre-clinical drug candidates and clinical research. From 2018 to 2019, Mr. Tan was the President of Avillion Berhad, a publicly listed travel and hospitality group with hotels, commercial property, and inbound/outbound travel services.
New Risk • Aug 17New major risk - Revenue and earnings growthEarnings have declined by 7.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (67% average weekly change). Earnings have declined by 7.8% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (US$11.5m market cap).
Reported Earnings • Aug 17Second quarter 2023 earnings released: US$0.001 loss per share (vs US$0.01 loss in 2Q 2022)Second quarter 2023 results: US$0.001 loss per share. Revenue: US$2.57m (up 3.3% from 2Q 2022). Net loss: US$259.3k (loss widened 87% from 2Q 2022).
New Risk • Jul 26New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (70% average weekly change). Minor Risks Shareholders have been diluted in the past year (9.9% increase in shares outstanding). Market cap is less than US$100m (US$55.7m market cap).
Board Change • Jul 21High number of new and inexperienced directorsThere are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. COO & Executive Director Liong Tan is the most experienced director on the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공시 • Feb 16BioNexus Gene Lab Corporation has filed an IPO in the amount of $17.25 million.BioNexus Gene Lab Corporation has filed an IPO in the amount of $17.25 million. Security Name: Common Stock Security Type: Common Stock
공시 • Aug 18+ 1 more updateBionexus Gene Lab Corporation Announces Management ChangesBioNexus Gene Lab Corporation announced that on August 9, 2022, Mr. Soo Kow Lai, the Chairman and director, Mr. Chan Chong Wong, the Chief Executive Officer and director, and Mr. Chi Yuen Leong, the President and director, notified that their desire to resign from their positions at the Company. The Company and Mr. Soo Kow Lai, Mr. Chan Chong Wong, and Mr. Chi Yuen Leong agreed that the resignations would be effective August 12, 2022. Mr. Soo Kow Lai, Mr. Chan Chong Wong, and Mr. Chi Yuen Leong’s resignations do not involve any disagreement on any matter relating to the Company’s operations, policies or practices (financial or otherwise), but were in order to pursue other commitments. On August 9, 2022, the Board of Directors of the Company approved the appointments of Mr. Yeat Min Fong as the Chairman and director, Mr. Sook Keng Yeoh as director, and Ms. Yee Meng Wong as the President and director, effective August 9, 2022. The biographical information of Mr. Yeat Min Fong, Mr. Sook Keng Yeoh, and Mr. Yee Meng Wong are set out below: Mr. Yeat Min Fong, age 43, has over 15 years of extensive experience in the medical industry. From 2020 to 2022, Mr. Fong was the Country General Manager of Malaysia of Doctor Anywhere, responsible for all business activities in the country. From 2014 to 2020, Mr. Fong acted as the General Manager/Medical Director of iHeal Medical Centre, where he performed numerous heart surgeries. Before entering the private medical industry, Mr. Fong engaged in various public hospitals in Malaysia for seven years. Mr. Fong holds a Bachelor of Medicine and Bachelor of Surgery from Manipal Acade MY of Higher Education in Manipal, India and a Master of Business Administration from the University of Cardiff Metropolitan in the UK. Mr. Sook Keng Yeoh, age 63, has over 41 years of extensive experience in management. From 2019 to 2022, Mr. Yeoh served as a director at ADS Sentral Sdn Bhd. From 1999 to 2019, Mr. Yeoh was the Chief Financial Officer and Finance Director of TRC Synergy Bhd., the Chief Executive Officer of TRC Energy Sdn Bhd. and the Executive Director of PetroBru (B) Sdn Bhd., a TRC Group. Mr. Yeoh holds a Bachelor of Commerce in Accounting, Finance, and Systems from the University of New South Wales (Australia) and a Chartered Accountant with the Malaysian Institute of Accountants. Ms. Yee Meng Wong, age 37, has many experiences in the biochemical industry and more than ten years of research experience. From 2016 to 2022, Ms. Wong served as a tutor and a lecturer at Monash University and as a consultant with Biomass Power Plant, Soybean Waste Aerobic Composting Plant, Deep Tech Startup Ultra Battery, and Food Safety & Handling, where she solved a series of biotech issues.
공시 • Apr 03BioNexus Gene Lab Corporation announced delayed annual 10-K filingOn 04/01/2022, BioNexus Gene Lab Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.
공시 • May 18BioNexus Gene Lab Corporation announced delayed 10-Q filingOn 05/17/2021, BioNexus Gene Lab Corporation announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공시 • Jan 01BioNexus Gene Lab Corporation (OTCPK:BGLC) agreed to acquire Chemrex Corporation Sdn. Bhd.BioNexus Gene Lab Corporation (OTCPK:BGLC) agreed to acquire Chemrex Corporation Sdn. Bhd. on December 24, 2020. Under terms, BioNexus Gene Lab Corporation will issue 68.48 million shares. As of December 31, 2019 Chemrex generated a revenue of $15.6 million and net income of $.30 million. Post acquisition Chemrex will become wholly-owned subsidiary of BioNexus. The transaction is subject to regulatory approvals. The transaction is expected to close on December 31, 2020.